Showing 1371-1380 of 5771 results for "".
- 4DMT Announces Phase 2 PRISM Interim Results for Intravitreal 4D-150 in Wet AMDhttps://modernod.com/news/4dmt-announces-phase-2-prism-interim-results-for-intravitreal-4d-150-in-wet-amd/2482364/4D Molecular Therapeutics announced initial interim 24-week landmark data from the population extension cohort of the PRISM phase 2 clinical trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, MD, at the A
- OcuCell Announces Funding from AltruVision and New Board Appointmentshttps://modernod.com/news/ocucell-announces-funding-from-altruvision-and-leadership-changes/2482354/OcuCell announced it has received funding from AltruVision to enable OcuCell to continue advancing its Endo-Tek and Epi-Tek ocular cell therapy treatments. Financial terms of the funding were not disclosed. Established in 1957, AltruVision recovers over 1,500 eye don
- Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMDhttps://modernod.com/news/opthea-announces-publication-on-vegf-c-and-d-signaling-pathways-as-potential-targets-for-treatment-of-wet-amd/2482348/Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication,
- Notal Vision Announces Results From Prospective Trial Using Home-Based OCThttps://modernod.com/news/notal-vision-announces-results-from-prospective-trial-using-home-based-oct/2482331/Notal Vision announced the results from the first prospective clinical trial using home-based optical coherence tomography (OCT) to manage wet age-related macular degeneration (AMD) patients in an investigational setting. The results, which were published in Retina, demonstrated a
- Rayner Announces New Appointments to Management Boardhttps://modernod.com/news/rayner-announces-new-appointments-to-management-board/2482311/Rayner announced three new appointments to its management board. James Crutchlow has been appointed Chief Commercial Officer; Rob Nadler was named Chief Growth Officer; and Chris Willis was named Chief Marketing Officer, effective immediately. “T
- Harrow Announces 52-Week Data from Vevye ESSENCE-2 Open-Label Extension Studyhttps://modernod.com/news/harrow-announces-52-week-data-from-vevye-essence-2-open-label-extension-study/2482309/Harrow has announced results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a phase 3, prospective, multicent
- Zeiss Announces OCT Enhancements to Cirrus 6000https://modernod.com/news/zeiss-announces-oct-enhancements-to-cirrus-6000/2482299/Zeiss Medical Technology announced enhancements to the Cirrus 6000 designed to allow for a more efficient and data-driven workflow for ophthalmologists. The device is supported by the largest OCT reference database in the US market, according to Zeiss, as well a
- Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopiahttps://modernod.com/news/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/2482295/Dopavision announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). MyopiaX delivers targeted photobiomodulation to the eye with the aim of managing the progression of myopia among children. The 6-month outcomes of the randomized, controlled tria
- Staar Surgical Announces Agreement in US with IQ Laser Visionhttps://modernod.com/news/staar-surgical-announces-agreement-in-us-with-iq-laser-vision/2482269/Staar Surgical announced a strategic agreement with IQ Laser Vision, which has locations across California and Texas. IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D. IQ Laser V
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in GAhttps://modernod.com/news/annexon-presents-new-neuroprotection-data-showing-anx007-protects-vision-and-vision-associated-structures-in-ga/2482268/Annexon presented new analyses of ANX007 from the phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated